Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Diverse genetic alterations in triple-negative breast cancers after neoadjuvant chemotherapy

SABCS 2012

Published: 6 Dec 2012

Views: 4545

Rating:

Save

Dr Justin Balko - Vanderbilt-Ingram Cancer Center, Nashville, USA

Many different genetic alterations were detected in tumour cells left behind after patients with triple-negative breast cancer were treated with chemotherapy prior to surgery (neoadjuvant chemotherapy), according to data presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium.

Read more in ecancernews.

Categories:
Breast
Cytotoxics
Surgery

Related Videos

Laser oncosurgery - A new perspective in treating cancer

Dr Rusy Bhalla - Orchid Center For Laser Surgery, Mumbai, India

Laser oncosurgery - A new perspective in treating cancer ( Dr Rusy Bhalla - Orchid Center For Laser Surgery, Mumbai, India )

ESMO 2024: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2024: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

ESMO 2024: Latest in bladder cancer - expert review

Dr Patrizia Giannatempo, Prof Andrea Necchi, Prof Simon Crabb, Dr Michiel Van Der Heijden

ESMO 2024: Latest in bladder cancer - expert review ( Dr Patrizia Giannatempo, Prof Andrea Necchi, Prof Simon Crabb, Dr Michiel Van Der Heijden )

Improved structure preservation with neo-adjuvant platinum-based chemo in patients with resectable NPNSCC

Prof Nabil F. Saba - Winship Cancer Institute of Emory University, Atlanta, USA

Improved structure preservation with neo-adjuvant platinum-based chemo in patients with resectable NPNSCC ( Prof Nabil F. Saba - Winship Cancer Institute of Emory University, Atlanta, USA )

Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer

Dr Nancy Lin - Dana-Farber Cancer Institute, Boston, USA

Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer ( Dr Nancy Lin - Dana-Farber Cancer Institute, Boston, USA )

Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival outcomes in HR and HER2 positive early BC

Dr Oleg Gluz - Evangeliches Krankenhaus Bethesda Klinik, Mönchengladbach, Germany

Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival outcomes in HR and HER2 positive early BC ( Dr Oleg Gluz - Evangeliches Krankenhaus Bethesda Klinik, Mönchengladbach, Germany )

Bladder cancer updates from the first half of 2024

Prof Alison Birtle, Dr Ignacio Durán, Dr Patrizia Giannatempo

Bladder cancer updates from the first half of 2024 ( Prof Alison Birtle, Dr Ignacio Durán, Dr Patrizia Giannatempo )

Neo-adjuvant therapy for different cancers in the Philippines

Dr Priscilla Caguioa - St Luke's Medical Center, Manila, Philippines

Neo-adjuvant therapy for different cancers in the Philippines ( Dr Priscilla Caguioa - St Luke's Medical Center, Manila, Philippines )

SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer

Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia

SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )

More from ecancer